Activating mutations in the RAS oncogene are common in cancer but are difficult to therapeutically target. RAS activation promotes autophagy, a highly regulated catabolic process that metabolically buffers cells in response to diverse stresses. Here we report that casein kinase 1α (CK1α), a ubiquitously expressed serine/threonine kinase, is a key negative regulator of oncogenic RAS–induced autophagy. Depletion or pharmacologic inhibition of CK1α enhanced autophagic flux in oncogenic RAS–driven human fibroblasts and multiple cancer cell lines. FOXO3A, a master longevity mediator that transcriptionally regulates diverse autophagy genes, was a critical target of CK1α, as depletion of CK1α reduced levels of phosphorylated FOXO3A and increased expression of FOXO3A-responsive genes. Oncogenic RAS increased CK1α protein abundance via activation of the PI3K/AKT/mTOR pathway. In turn, elevated levels of CK1α increased phosphorylation of nuclear FOXO3A, thereby inhibiting transactivation of genes critical for RAS-induced autophagy. In both RAS-driven cancer cells and murine xenograft models, pharmacologic CK1α inactivation synergized with lysosomotropic agents to inhibit growth and promote tumor cell death. Together, our results identify a kinase feedback loop that influences RAS-dependent autophagy and suggest that targeting CK1α-regulated autophagy offers a potential therapeutic opportunity to treat oncogenic RAS–driven cancers.
Authors
Jit Kong Cheong, Fuquan Zhang, Pei Jou Chua, Boon Huat Bay, Andrew Thorburn, David M. Virshup
(A) Activation of oncogenic H-RASV12 increases CK1α protein abundance in a time-dependent manner. BJ-derived fibroblasts were exposed to 4-OHT for the indicated times. (B) CSNK1A1 (CK1a) transcript abundance as assessed by qPCR was unchanged by H-RASV12 activation for 24 hours. (C) Loss of oncogenic RAS decreases CK1α protein abundance and autophagy. Isogenic HCT-116 cells (with or without mutant K-RAS) were analyzed by immunoblotting with the indicated antibodies. (D) Blockade of PI3K activity reduces CK1α protein abundance. BJhTERT/st/ER:H-RASV12 fibroblasts were exposed to 130 nM 4-OHT for 24 hours. Eighteen hours after the start of 4-OHT treatment, DMSO (Veh), SB203580 (SB; 10 μM), LY294002 (LY; 10 μM), or U0126 (U; 10 μM) was added to the cells for a further 6 hours of incubation prior to analysis by immunoblotting. (E) LY294002 reduces CK1α protein abundance in a time-dependent manner. Representative immunoblots of endogenous CK1α protein expression in BJhTERT/st/ER:H-RASV12 and HCT-116 cells treated with LY294002 for the indicated times. (F) Rapamycin reduces CK1α protein abundance in a time-dependent manner. Representative immunoblots of endogenous CK1α protein expression in BJhTERT/st/ER:H-RASV12 and HCT-116 cells treated with rapamycin for the indicated times. Fold expression change in the proteins of interest after normalization is shown below protein blots.